1
Hypotheses: Trial Duration/dyanimcs
Will King edited this page 4 years ago
following line of questioning Abrantes-Metz, Adams, & Metz questions revolve around the durations of trials.
specific questions
Does successful completion/other dynamics depend on the market for which the drug is being tested?
So, for example are trials more likely to terminate if there are a lot of other drugs on that market? Are trials more likely to last longer if it is a generic or other second to market?
Those types of questions can be answered by my dataset. Basically, do dynamics shift based on market saturation? How does that change across phases?
quantile duration
- Do trials whose trial duration was in a higher quantile remain within higher quantile for later trials? i.e. are durations stable?
- Is there a policy which shuffles durations?
- using quantile methods might allow one to create estimates including trials that are not complete.